Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
https://www.zacks.com/stock/news/2334180/summit-hits-record-high-on-lung-cancer-drug-topping-merck-s-keytruda?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334180
Sep 10, 2024 - Data from a late-stage study shows that SMMT's experimental antibody beat Keytruda in a head-to-head setting in treating certain patients with NSCLC.
0
MRK Stock Dips After SMMT's Cancer Drug Outshines Keytruda in Study
https://www.zacks.com/stock/news/2334056/mrk-stock-dips-after-smmt-s-cancer-drug-outshines-keytruda-in-study?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2334056
Sep 10, 2024 - Merck's Keytruda is the standard of care for NSCLC. Ivonescimab, however, shows clinically meaningful benefit over Keytruda in a phase III study in NSCLC.
0
Merck & Co., Inc. (MRK) CEO Rob Davis presents at Morgan Stanley 22nd Annual Global Healthcare Conference (Transcript)
https://seekingalpha.com/article/4719642-merck-and-co-inc-mrk-ceo-rob-davis-presents-morgan-stanley-22nd-annual-global-healthcare?source=feed_sector_transcripts
Sep 06, 2024 - Merck & Co., Inc. (NYSE:MRK) Morgan Stanley 22nd Annual Global Healthcare Conference September 5, 2024 2:35 PM ETCompany ParticipantsRob Davis -...
0
Pharma Stock Roundup: EU Nod for Expanded Use of MRK's Keytruda & More
https://www.zacks.com/stock/news/2332784/pharma-stock-roundup-eu-nod-for-expanded-use-of-mrk-s-keytruda-more?cid=CS-ZC-FT-analyst_blog|stock_roundup-2332784
Sep 06, 2024 - European Commission approves expanded use of Merck's Keytruda in bladder cancer. Sanofi & Lilly announce data from phase III studies on pipeline candidates.
0
Merck's Keytruda & Padcev Combo Gets EU Nod for Urothelial Carcinoma
https://www.zacks.com/stock/news/2331488/merck-s-keytruda-padcev-combo-gets-eu-nod-for-urothelial-carcinoma?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2331488
Sep 04, 2024 - MRK's Keytruda gets approval in combination with Astellas and Pfizer's Padcev for treating first-line advanced urothelial carcinoma.
0
Merck (MRK) Advances But Underperforms Market: Key Facts
https://www.zacks.com/stock/news/2329975/merck-mrk-advances-but-underperforms-market-key-facts?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_6-2329975
Aug 30, 2024 - In the most recent trading session, Merck (MRK) closed at $118.45, indicating a +0.84% shift from the previous trading day.
0
Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
https://www.zacks.com/stock/news/2329912/merck-scraps-two-late-stage-keytruda-studies-on-disappointing-data?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2329912
Aug 30, 2024 - MRK made this decision after an independent committee pointed out that Keytruda did not show improvement in certain types of lung and skin cancers.
0
Pharma Stock Roundup: LLY Offers Cheap Zepbound, EU Okays Some Drugs
https://www.zacks.com/stock/news/2329707/pharma-stock-roundup-lly-offers-cheap-zepbound-eu-okays-some-drugs?cid=CS-ZC-FT-analyst_blog|stock_roundup-2329707
Aug 30, 2024 - LLY launches a discounted version of Zepbound. European Commission approves JNJ's Balversa, MRK's Winrevair and RHHBY's PiaSky.
0
MRK Begins 2nd Phase III Study on Rare Blood Disorder Candidate
https://www.zacks.com/stock/news/2328478/mrk-begins-2nd-phase-iii-study-on-rare-blood-disorder-candidate?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2328478
Aug 28, 2024 - Merck begins the second phase III study on its LSD1 inhibitor, bomedemstat, for treating certain patients with essential thrombocythemia, a rare blood disorder.
0
12 Dividend Stocks to Earn Income Every Month
https://www.fool.com/investing/2024/08/28/12-dividend-stocks-to-earn-income-every-month/?source=iedfolrf0000001
Aug 28, 2024 - Get paid a dividend on a monthly basis.
0